Qualigen Therapeutics (AIXC) versus Its Competitors Head to Head Review

Qualigen Therapeutics (NASDAQ:AIXC) is one of 458 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its competitors? We will compare Qualigen Therapeutics to related businesses based on the strength of its risk, institutional ownership, valuation, dividends, profitability, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings for Qualigen Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
Qualigen Therapeutics Competitors	4898	9970	16002	378	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 67.26%. Given Qualigen Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Qualigen Therapeutics has less favorable growth aspects than its competitors.

Volatility & Risk

Qualigen Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics’ competitors have a beta of 5.62, meaning that their average share price is 462% more volatile than the S&P 500.

Profitability

This table compares Qualigen Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-52.57%
Qualigen Therapeutics Competitors	-2,662.44%	-364.10%	-42.99%

Earnings & Valuation

This table compares Qualigen Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Qualigen Therapeutics	N/A	-$6.26 million	-0.14
Qualigen Therapeutics Competitors	$432.18 million	-$67.78 million	-10.47

Qualigen Therapeutics’ competitors have higher revenue, but lower earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Qualigen Therapeutics competitors beat Qualigen Therapeutics on 9 of the 13 factors compared.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.